| 1 |
33619631 | Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. | 2021 Mar |
3 |
| 2 |
29932028 | Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity. | 2019 |
1 |
| 3 |
25689738 | Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study. | 2015 |
2 |
| 4 |
22740978 | Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. | 2012 Mar |
1 |
| 5 |
21297369 | [Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs]. | 2011 Feb |
1 |
| 6 |
21840303 | Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells. | 2011 Dec 1 |
2 |
| 7 |
17700594 | Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. | 2008 Jun |
1 |
| 8 |
17713471 | Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. | 2008 Apr |
1 |
| 9 |
18281753 | [CPT-11 (Irinotecan)]. | 2008 Feb |
1 |
| 10 |
16965601 | Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. | 2006 Nov |
1 |
| 11 |
12485959 | Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. | 2003 Jan |
1 |
| 12 |
11259359 | Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. | 2001 Apr |
1 |